TABLE 1.
Serovar | No. (%) of:
|
|||
---|---|---|---|---|
Women
|
Men
|
|||
Asymptomatic | Symptomatic | Asymptomatic | Symptomatic | |
Group B | ||||
D | 13 (5.7) | 8 (8.0) | 1 (1.5) | 2 (4.8) |
D− | 11 (4.8) | 9 (9.0) | 4 (6.1) | 3 (7.1) |
E | 94 (40.9) | 36 (36.0) | 32 (48.5) | 15 (35.7) |
Subtotal | 118 (51.4) | 53 (53.0) | 39 (56.1) | 20 (47.6) |
Intermediate group | ||||
F | 54 (23.5) | 18 (18.0) | 10 (15.2) | 11 (26.2) |
G | 13 (5.7) | 7 (7.0) | 5 (7.6) | 1 (2.4) |
Ga | 3 (1.3) | 1 (1.0) | 0 (0.0) | 6 (14.3) |
Subtotal | 70 (30.5) | 26 (26.0) | 15 (22.8) | 18 (43.1) |
Group C | ||||
H | 5 (2.2) | 4 (4.0) | 6 (7.6) | 1 (2.4) |
I | 3 (1.3) | 2 (2.0) | 1 (1.5) | 2 (4.8) |
Ia | 6 (2.6) | 0 (0.0) | 3 (4.5) | 0 (0.0) |
J | 12 (5.2) | 5 (5.0) | 2 (3.0) | 0 (0.0) |
K | 6 (2.6) | 7 (7.0) | 3 (4.5) | 1 (2.4) |
Subtotal | 32 (13.9) | 18 (18.0) | 15 (21.1) | 4 (9.6) |
Variants | 10 (4.3) | 3 (3.0) | 0 (0.0) | 0 (0.0) |
Total | 230 (52.5) | 100 (22.8) | 66 (15.1) | 42 (9.6) |